• 
  Grégoire Marret, Stéphane Temam, Maud Kamal, Caroline Even, Jean-Pierre Delord, et al.. Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity. Scientific Reports, 2023, 13, pp.22524. ⟨10.1038/s41598-023-49887-4⟩. ⟨hal-04543900⟩
• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Justine Gantzer, Maud Toulmonde, François Séverac, Ali N. Chamseddine, Celine Charon-Barra, et al.. PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent. Cancer, 2024, ⟨10.1002/cncr.35277⟩. ⟨hal-04533834⟩
• 
  Jean-Marc Classe, Gilles Dolivet, Serge Evrard, Gwenael Ferron, Fabrice Lécuru, et al.. Recommandations de la Société française de chirurgie oncologique (SFCO) pour l’organisation de la chirurgie oncologique durant l’épidémie de COVID-19. Bulletin du Cancer, 2020, 107 (5), pp.524-527. ⟨10.1016/j.bulcan.2020.03.010⟩. ⟨hal-02988833⟩
• 
  P. Sargos, J. Le Guevelou, J. Khalifa, L. Albiges, D. Azria, et al.. The role of radiation therapy for de novo metastatic bladder and renal cancers. Cancer/Radiothérapie, 2024, 28 (1), pp.56 - 65. ⟨10.1016/j.canrad.2023.02.004⟩. ⟨inserm-04517309⟩
• 
  Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, et al.. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. npj Breast Cancer, 2017, 3 (1), pp.4. ⟨10.1038/s41523-017-0005-y⟩. ⟨cea-04501580⟩
• 
  Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault de La Motte Rouge, Thierry Petit, et al.. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 2024, ⟨10.1007/s10549-024-07285-y⟩. ⟨hal-04495069⟩
• 
  Thibaud Charrier, Brice Fresneau, Nadia Haddy, Boris Schwartz, Neige Journy, et al.. Increased Cardiac Risk After a Second Malignant Neoplasm Among Childhood Cancer Survivors, a FCCSS Study. RADRES, Oct 2022, Waikoloa, United States. ⟨hal-04488310⟩
• 
  Charlotte Demoor-Goldschmidt, Pascal Veillon, Maxime Esvan, Mathilde Leonard, Sophie Chauvet, et al.. A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility. BMC Cancer, 2024, Bmc Cancer, 24 (1), pp.130. ⟨10.1186/s12885-024-11857-y⟩. ⟨hal-04484217⟩
• 
  Julien Jurczak, Benjamin Rapp, jean-marc bordy, Stéphanie Josset, Stephane Dufreneix. Defining field output factors in small fields based on dose area product measurements: a feasibility study. Medical Physics, 2024, ⟨10.1002/mp.16950⟩. ⟨cea-04457936⟩
• 
  Charlotte Demoor-Goldschmidt, Stéphane Supiot, Marc-André Mahé, Odile Oberlin, Rodrigue Allodji, et al.. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. British Journal of Radiology, 2018, 91 (1086), pp.20170824. ⟨10.1259/bjr.20170824⟩. ⟨inserm-04439735⟩
• 
  Imène Mansouri, Rodrigue S Allodji, Catherine Hill, Chiraz El‐fayech, François Pein, et al.. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. European Journal of Heart Failure, 2018, 21 (4), pp.509 - 518. ⟨10.1002/ejhf.1376⟩. ⟨inserm-04439245⟩
• 
  Grégory Delpon, Alexandre Escande, Timothée Ruef, Julien Darréon, Jimmy Fontaine, et al.. Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy. Frontiers in Oncology, 2016, 6, ⟨10.3389/fonc.2016.00178⟩. ⟨hal-01683878⟩
• 
  Catherine M. Phelan, Karoline B. Kuchenbaecker, Jonathan Tyrer, Siddhartha Kar, Kate Lawrenson, et al.. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49 (5), pp.680-691. ⟨10.1038/ng.3826⟩. ⟨hal-01778538⟩
• 
  Arthur Petat, Eric Dansin, Fabien Calcagno, Laurent Greillier, Eric Pichon, et al.. Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. European Journal of Cancer, 2022, 162, pp.118-127. ⟨10.1016/j.ejca.2021.11.028⟩. ⟨hal-03524368⟩
• 
  Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
• 
  Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, et al.. A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩. ⟨hal-03469622⟩
• 
  Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, et al.. Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers, 2022, 14 (7), pp.1678. ⟨10.3390/cancers14071678⟩. ⟨hal-04327308⟩
• 
  Manon de Vries-Brilland, Nathalie Rioux-Leclercq, Maxime Meylan, Jonathan Dauvé, Christophe Passot, et al.. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩. ⟨hal-04341909⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩

233

286